Establishment of opioid-induced rewarding effects under oxaliplatin- and paclitaxel-induced neuropathy in rats

Journal of Pharmacological Sciences

Volumn 126, Issue 1, 2014, Pages 47-55

  Mori, Tomohisa ^a   Kanbara, Tomoe ^a,b   Harumiya, Masato ^a   Iwase, Yoshiyuki ^a   Masumoto, Aki ^a   Komiya, Sachiko ^a   Nakamura, Atsushi ^a,b   Shibasaki, Masahiro ^a   Kanemasa, Toshiyuki ^b   Sakaguchi, Gaku ^b   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Neuropathic pain; Oxaliplatin; Paclitaxel; Rewarding effect; Opioid receptor agonist

Indexed keywords

DOPAMINE; FENTANYL; MORPHINE; OXALIPLATIN; OXYCODONE; PACLITAXEL; ANTINEOPLASTIC AGENT; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PLATINUM COMPLEX;

ADVERSE OUTCOME; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; MALE; NEUROPATHIC PAIN; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REWARD; VON FREY TEST; AGONISTS; ANIMAL; CHEMICALLY INDUCED; NEURALGIA; SPRAGUE DAWLEY RAT; SUBSTANCE-RELATED DISORDERS;

ANALGESICS, OPIOID; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FENTANYL; MALE; MORPHINE; NEURALGIA; ORGANOPLATINUM COMPOUNDS; OXYCODONE; PACLITAXEL; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SUBSTANCE-RELATED DISORDERS;

EID: 84909969600     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14134FP     Document Type: Article

References (30)

1. Woodcock J. A difficult balance - pain management, drug safety, and the FDA. N Engl J Med. 2009;361:2105-2107.
2. Liu SB, Ma L, Guo HJ, Feng B, Guo YY, Li XQ, et al. Gentiopicroside attenuates morphine rewarding effect through downregulation of GluN2B receptors in nucleus accumbens. CNS Neurosci Ther. 2012;18:652-658.
3. Popik P, Mamczarz J, Fraczek M, Widla M, Hesselink M, Danysz W. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology. 1998;37:1033-1042.
4. Valjent E, Corbille AG, Bertran-Gonzalez J, Herve D, Girault JA. Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci U S A. 2006;103:2932-2937.
5. Benturquia N, Le Marec T, Scherrmann JM, Noble F. Effects of nitrous oxide on dopamine release in the rat nucleus accumbens and expectation of reward. Neuroscience. 2008;155:341-344.
6. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171-191.
7. Nestler EJ. Under siege: the brain on opiates. Neuron. 1996;16:897-900.
8. Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res. 1991;566:348-350.
9. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of non-malignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293:3043-3052.
10. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.
11. Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology. 2005;30:111-118.
12. Ozaki S, Narita M, Iino M, Sugita J, Matsumura Y, Suzuki T. Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area. J Neurochem. 2002;82:1192-1198.
13. Suzuki T, Kishimoto Y, Misawa M. Formalin- and carrageenan-induced inflammation attenuates place preferences produced by morphine, methamphetamine and cocaine. Life Sci. 1996;59:1667-1674.
14. Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T. Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci. 2010;31:299-305.
15. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438-444.
16. Inoue K, Nagai S, Kaneko S, Uchida S, Hayashi Y, Higuchi T, et al. [Efficacy of oxycodone against anti-cancer agent-induced pain in breast cancer patients during adjuvant treatment before and after surgery]. Gan To Kagaku Ryoho. 2011;38:1137-1142. (text in Japanese with English abstract)
17. Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, et al. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer. 2014;22:1579-1584.
18. Baron R, Tolle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009;146:34-40.
19. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35:31-39.
20. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507-1515.
21. Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience. 2001;108:507-515.
22. Suzuki T, Funada M, Narita M, Misawa M, Nagase H. Pertussis toxin abolishes mu- and delta-opioid agonist-induced place preference. Eur J Pharmacol. 1991;205:85-88.
23. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205-218.
24. Liu S, Kopacz DJ, Carpenter RL. Quantitative assessment of differential sensory nerve block after lidocaine spinal anesthesia. Anesthesiology. 1995;82:60-63.
25. Masson EA, Boulton AJ. The Neurometer: validation and comparison with conventional tests for diabetic neuropathy. Diabet Med. 1991;8:S63-S66.
26. Pitei DL, Watkins PJ, Stevens MJ, Edmonds ME. The value of the Neurometer in assessing diabetic neuropathy by measurement of the current perception threshold. Diabet Med. 1994;11:872-876.
27. Tay B, Wallace MS, Irving G. Quantitative assessment of differential sensory blockade after lumbar epidural lidocaine. Anesth Analg. 1997;84:1071-1075.
28. Liu YL, Yan LD, Zhou PL, Wu CF, Gong ZH. Levo-tetrahydropalmatine attenuates oxycodone-induced conditioned place preference in rats. Eur J Pharmacol. 2009;602:321-327.
29. Miller DK, Nation JR. Chronic cadmium exposure attenuates the conditioned reinforcing properties of morphine and fentanyl. Brain Res. 1997;776:162-169.
30. Suzuki R, Chapman V, Dickenson AH. The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain. 1999;80:215-228.